Shroff Rukshana C, Shah Vanita, Hiorns Melanie P, Schoppet Michael, Hofbauer Lorenz C, Hawa Gerhard, Schurgers Leon J, Singhal Atul, Merryweather Ian, Brogan Paul, Shanahan Catherine, Deanfield John, Rees Lesley
Nephrourology Unit, Great Ormond Street Hospital & UCL Institute of Child Health, London WC1N 1EH, UK.
Nephrol Dial Transplant. 2008 Oct;23(10):3263-71. doi: 10.1093/ndt/gfn226. Epub 2008 May 7.
Vascular calcification occurs in the majority of patients with chronic kidney disease, but a subset of patients does not develop calcification despite exposure to a similar uraemic environment. Physiological inhibitors of calcification, fetuin-A, osteoprotegerin (OPG) and undercarboxylated-matrix Gla protein (uc-MGP) may play a role in preventing the development and progression of ectopic calcification, but there are scarce and conflicting data from clinical studies.
We measured fetuin-A, OPG and uc-MGP in 61 children on dialysis and studied their associations with clinical, biochemical and vascular measures.
Fetuin-A and OPG were higher and uc-MGP lower in dialysis patients than controls. In controls, fetuin-A and OPG increased with age. Fetuin-A showed an inverse correlation with dialysis vintage (P = 0.0013), time-averaged serum phosphate (P = 0.03) and hs-CRP (P = 0.001). Aortic pulse wave velocity (PWV) and augmentation index showed a negative correlation with fetuin-A while a positive correlation was seen with PWV and OPG. Patients with calcification had lower fetuin-A and higher OPG than those without calcification. On multiple linear regression analysis Fetuin-A independently predicted aortic PWV (P = 0.004, beta = -0.45, model R(2) = 48%) and fetuin-A and OPG predicted cardiac calcification (P = 0.02, beta = -0.29 and P = 0.014, ss = 0.33, respectively, model R(2) = 32%).
This is the first study to define normal levels of the calcification inhibitors in children and show that fetuin-A and OPG are associated with increased vascular stiffness and calcification in children on dialysis. Higher levels of fetuin-A in children suggest a possible protective upregulation of fetuin-A in the early stages of exposure to the pro-calcific and pro-inflammatory uraemic environment.
大多数慢性肾病患者会发生血管钙化,但有一部分患者尽管处于相似的尿毒症环境中却未出现钙化。钙化的生理抑制剂,胎球蛋白-A、骨保护素(OPG)和未羧化基质Gla蛋白(uc-MGP)可能在预防异位钙化的发生和进展中发挥作用,但临床研究的数据稀缺且相互矛盾。
我们测量了61名接受透析的儿童的胎球蛋白-A、OPG和uc-MGP,并研究了它们与临床、生化及血管指标的相关性。
透析患者的胎球蛋白-A和OPG高于对照组,而uc-MGP低于对照组。在对照组中,胎球蛋白-A和OPG随年龄增加。胎球蛋白-A与透析龄(P = 0.0013)、时间平均血清磷酸盐(P = 0.03)和hs-CRP(P = 0.001)呈负相关。主动脉脉搏波速度(PWV)和增强指数与胎球蛋白-A呈负相关,而与PWV和OPG呈正相关。有钙化的患者比无钙化的患者胎球蛋白-A更低而OPG更高。多元线性回归分析显示,胎球蛋白-A独立预测主动脉PWV(P = 0.004,β = -0.45,模型R² = 48%),胎球蛋白-A和OPG预测心脏钙化(分别为P = 0.02,β = -0.29和P = 0.014,ss = 0.33,模型R² = 32%)。
这是第一项确定儿童钙化抑制剂正常水平的研究,并表明胎球蛋白-A和OPG与接受透析儿童的血管僵硬度增加和钙化有关。儿童中较高水平的胎球蛋白-A表明在暴露于促钙化和促炎的尿毒症环境的早期阶段,胎球蛋白-A可能存在保护性上调。